ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
R2r11
|
13K |
5.0M |
11 |
19/09/20 |
19/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
11
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
R2r11
|
13K |
5.0M |
1 |
18/09/20 |
18/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: ODAC Votes in Favor of Remestemcel-L for GvHD
|
|
R2r11
|
142 |
66K |
12 |
17/09/20 |
17/09/20 |
ASX - By Stock
|
142
|
66K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Wins Fierce Biotech Innovation Award for Remestemcel-L
|
|
R2r11
|
231 |
103K |
1 |
16/09/20 |
16/09/20 |
ASX - By Stock
|
231
|
103K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Who is the greatest Mesoblast shareholder of them all?
|
|
R2r11
|
45 |
15K |
5 |
15/09/20 |
15/09/20 |
ASX - By Stock
|
45
|
15K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
R2r11
|
576 |
234K |
1 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
576
|
234K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
R2r11
|
13K |
5.0M |
0 |
11/09/20 |
11/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
0
|
|
ASX - By Stock
|
CYP |
Re:
Stem cell injection for Cyp management
|
|
R2r11
|
133 |
28K |
0 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
133
|
28K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
5 |
09/09/20 |
09/09/20 |
ASX - By Stock
|
17K
|
6.7M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
5 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
17K
|
6.7M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
0 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
17K
|
6.7M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Pick the Closing Price after FDA approval on that day
|
|
R2r11
|
449 |
189K |
0 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
449
|
189K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
R2r11
|
13K |
5.0M |
0 |
06/09/20 |
06/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
R2r11
|
576 |
234K |
4 |
06/09/20 |
06/09/20 |
ASX - By Stock
|
576
|
234K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
R2r11
|
320 |
129K |
1 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
129K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
R2r11
|
320 |
129K |
2 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
129K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
R2r11
|
320 |
129K |
8 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
129K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
R2r11
|
320 |
129K |
4 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
129K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
R2r11
|
320 |
129K |
3 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
129K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
R2r11
|
320 |
129K |
9 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
129K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
R2r11
|
320 |
129K |
6 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
129K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
R2r11
|
320 |
129K |
9 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
129K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
R2r11
|
320 |
129K |
5 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
129K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
R2r11
|
13K |
5.0M |
1 |
28/08/20 |
28/08/20 |
ASX - By Stock
|
13K
|
5.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
70% (!) of their 90 patients with severe to moderate COVID-19 infections have been taken off ventilators
|
|
R2r11
|
75 |
43K |
0 |
28/08/20 |
28/08/20 |
ASX - By Stock
|
75
|
43K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
12 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
17K
|
6.7M
|
12
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
R2r11
|
9.8K |
2.9M |
1 |
26/08/20 |
26/08/20 |
ASX - By Stock
|
9.8K
|
2.9M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19
|
|
R2r11
|
425 |
190K |
4 |
26/08/20 |
26/08/20 |
ASX - By Stock
|
425
|
190K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
R2r11
|
576 |
234K |
4 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
576
|
234K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
R2r11
|
13K |
5.0M |
10 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
13K
|
5.0M
|
10
|
|
ASX - By Stock
|
MSB |
Re:
MESOBLAST- FUNDAMENTALS discussions
|
|
R2r11
|
305 |
115K |
30 |
22/08/20 |
22/08/20 |
ASX - By Stock
|
305
|
115K
|
30
|
|
ASX - By Stock
|
MSB |
Re:
MSB-CYP- Can we compare them?
|
|
R2r11
|
22 |
8.6K |
0 |
21/08/20 |
21/08/20 |
ASX - By Stock
|
22
|
8.6K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
MSB-CYP- Can we compare them?
|
|
R2r11
|
22 |
8.6K |
1 |
21/08/20 |
21/08/20 |
ASX - By Stock
|
22
|
8.6K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
R2r11
|
5.4K |
2.7M |
3 |
18/08/20 |
18/08/20 |
ASX - By Stock
|
5.4K
|
2.7M
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - Most exciting 6 months
|
|
R2r11
|
729 |
372K |
2 |
17/08/20 |
17/08/20 |
ASX - By Stock
|
729
|
372K
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - Most exciting 6 months
|
|
R2r11
|
729 |
372K |
10 |
16/08/20 |
16/08/20 |
ASX - By Stock
|
729
|
372K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
R2r11
|
13K |
5.0M |
2 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
13K
|
5.0M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
$5 party?
|
|
R2r11
|
108 |
41K |
8 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
108
|
41K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Naysayers
|
|
R2r11
|
10 |
2.1K |
3 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
10
|
2.1K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
ODAC voting results
|
|
R2r11
|
80 |
27K |
6 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
80
|
27K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
R2r11
|
203 |
89K |
14 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
203
|
89K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Scheduled FDA Advisory Committee Meeting
|
|
R2r11
|
176 |
88K |
1 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
176
|
88K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Scheduled FDA Advisory Committee Meeting
|
|
R2r11
|
176 |
88K |
0 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
176
|
88K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - Aug 2020 on
|
|
R2r11
|
2.3K |
905K |
0 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
2.3K
|
905K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Scheduled FDA Advisory Committee Meeting
|
|
R2r11
|
176 |
88K |
5 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
176
|
88K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - Aug 2020 on
|
|
R2r11
|
2.3K |
905K |
2 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
2.3K
|
905K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
R2r11
|
5.4K |
2.7M |
3 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
5.4K
|
2.7M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
R2r11
|
5.4K |
2.7M |
0 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
5.4K
|
2.7M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
R2r11
|
5.4K |
2.7M |
0 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
5.4K
|
2.7M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
R2r11
|
5.4K |
2.7M |
0 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
5.4K
|
2.7M
|
0
|
|